ERBB2 and breast cancer: The overall survival of patients suffering from HER2-enriched breast cancer with high chronic inflammatory signatures, regardless of the carbonic anhydrase expression level, is very similar to that in less inflamed tumors with high carbonic anhydrase levels (compare Fig. 11H, I).